- Home
- OPRT vs IFRX Comparison
OPRT vs IFRX Comparison
Compare OPRT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- IFRX
- Stock Information
- Founded
- OPRT 2005
- IFRX 2007
- Country
- OPRT United States
- IFRX Germany
- Employees
- OPRT N/A
- IFRX N/A
- Industry
- OPRT Finance: Consumer Services
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- OPRT Finance
- IFRX Health Care
- Exchange
- OPRT Nasdaq
- IFRX Nasdaq
- Market Cap
- OPRT 146.4M
- IFRX 143.7M
- IPO Year
- OPRT 2019
- IFRX 2017
- Fundamental
- Price
- OPRT $3.93
- IFRX $2.54
- Analyst Decision
- OPRT Buy
- IFRX Strong Buy
- Analyst Count
- OPRT 4
- IFRX 1
- Target Price
- OPRT $5.17
- IFRX $8.00
- AVG Volume (30 Days)
- OPRT 187.8K
- IFRX 174.5K
- Earning Date
- OPRT 03-11-2025
- IFRX 11-08-2024
- Dividend Yield
- OPRT N/A
- IFRX N/A
- EPS Growth
- OPRT N/A
- IFRX N/A
- EPS
- OPRT N/A
- IFRX N/A
- Revenue
- OPRT $796,991,000.00
- IFRX $187,930.00
- Revenue This Year
- OPRT N/A
- IFRX $392.79
- Revenue Next Year
- OPRT $2.36
- IFRX $156.76
- P/E Ratio
- OPRT N/A
- IFRX N/A
- Revenue Growth
- OPRT N/A
- IFRX 177.12
- 52 Week Low
- OPRT $2.05
- IFRX $1.17
- 52 Week High
- OPRT $4.60
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- OPRT 55.34
- IFRX 56.66
- Support Level
- OPRT $3.45
- IFRX $2.16
- Resistance Level
- OPRT $3.95
- IFRX $2.65
- Average True Range (ATR)
- OPRT 0.17
- IFRX 0.24
- MACD
- OPRT -0.02
- IFRX -0.01
- Stochastic Oscillator
- OPRT 57.83
- IFRX 63.33
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.